Amgen adds gastric cancer drug candidate in $1.9 billion Five Prime Therapeutics deal

Amgen adds gastric cancer drug candidate in $1.9 billion Five Prime Therapeutics deal

Source: 
Reuters
snippet: 

Drugmaker Amgen Inc will pay about $1.9 billion in cash for Five Prime Therapeutics, adding a late-stage gastric cancer drug candidate to its line of cancer drugs, the companies said on Thursday.